Pancreatic cancer is a common pancreatic tumor, and its incidence has been increasing significantly in recent years. The literature reports that the survival of patients with untreated pancreatic cancer is about 4 months, that of patients treated with bypass surgery is about 7 months, and that patients generally survive 16 months after resection surgery, which is one of the malignant tumors with the worst prognosis. Since pancreatic cancer is not sensitive to radiotherapy and chemotherapy, surgery has become the main treatment for pancreatic cancer. Since pancreatic cancer easily invades the vasculature and nerve tissue, the recurrence and metastasis rate after surgery is high and the prognosis is poor. The most common sites of recurrent metastasis are lymph nodes and liver. For liver metastasis, there is no effective preventive measure, but for retroperitoneal local recurrence and lymph node metastasis, they should be controlled from the perspective of surgery. Under the current medical conditions, the simple removal of the tumor itself during surgery is far from the requirement of radical tumor resection. It is important to completely remove the lymph nodes in the area of tumor drainage. For pancreatic head cancer, in addition to the routine removal of lymph nodes around the intrinsic hepatic artery and common hepatic artery, attention should be paid to the removal of lymph nodes around the beginning of splenic artery, celiac artery and superior mesenteric artery, and the removal of lymph nodes between the inferior vena cava, left renal vein and abdominal aorta. For tumors in the tail of the pancreatic body, in addition to the usual removal of the spleen to remove the lymph nodes in the splenic hilum, attention should be paid to the removal of the lymph nodes around the beginning of the splenic artery, the celiac trunk, the superior mesenteric artery and the middle colonic artery.